Carnegie Investment Counsel’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10.3M Sell
85,461
-1,254
-1% -$145K 0.2% 130
2025
Q4
$9.13M Buy
86,715
+11,849
+16% +$1.11M 0.17% 144
2025
Q3
$6.28M Buy
74,866
+9,342
+14% +$769K 0.12% 158
2025
Q2
$5.19M Buy
65,524
+2,128
+3% +$169K 0.1% 170
2025
Q1
$5.22M Buy
63,396
+32,663
+106% +$3.05M 0.12% 159
2024
Q4
$3.06M Buy
30,733
+2,684
+10% +$277K 0.09% 172
2024
Q3
$3.19M Sell
28,049
-1,056
-4% -$125K 0.09% 170
2024
Q2
$3.6M Sell
29,105
-5,533
-16% -$713K 0.11% 154
2024
Q1
$4.57M Buy
34,638
+102
+0.3% +$12.6K 0.14% 150
2023
Q4
$3.77M Sell
34,536
-7,548
-18% -$783K 0.13% 158
2023
Q3
$4.33M Sell
42,084
-1,366
-3% -$147K 0.17% 138
2023
Q2
$5.01M Sell
43,450
-1,114
-2% -$126K 0.19% 132
2023
Q1
$4.74M Sell
44,564
-2,949
-6% -$318K 0.19% 131
2022
Q4
$5.27M Buy
47,513
+3,900
+9% +$399K 0.23% 113
2022
Q3
$3.76M Buy
43,613
+75
+0.2% +$6.7K 0.18% 134
2022
Q2
$3.97M Buy
43,538
+5,160
+13% +$457K 0.18% 132
2022
Q1
$3.15M Buy
38,378
+5,011
+15% +$395K 0.11% 167
2021
Q4
$2.56M Buy
33,367
+3,840
+13% +$306K 0.08% 186
2021
Q3
$2.22M Sell
29,527
-346
-1% -$26.3K 0.08% 174
2021
Q2
$2.32M Buy
29,873
+590
+2% +$43.9K 0.09% 177
2021
Q1
$2.15M Buy
29,283
+1,280
+5% +$94.4K 0.09% 178
2020
Q4
$2.19M Sell
28,003
-605
-2% -$46.3K 0.1% 168
2020
Q3
$2.26M Sell
28,608
-554
-2% -$43.4K 0.12% 151
2020
Q2
$2.15M Buy
29,162
+133
+0.5% +$10K 0.12% 153
2020
Q1
$2.13M Sell
29,029
-807
-3% -$63.4K 0.15% 141
2019
Q4
$2.59M Buy
29,836
+421
+1% +$34.6K 0.15% 147
2019
Q3
$2.36M Sell
29,415
-210
-0.7% -$16.8K 0.15% 147
2019
Q2
$2.37M Sell
29,625
-67
-0.2% -$5.13K 0.15% 146
2019
Q1
$2.36M Sell
29,692
-465
-2% -$34.8K 0.16% 134
2018
Q4
$2.2M Sell
30,157
-7,831
-21% -$553K 0.2% 126
2018
Q3
$2.76M Buy
37,988
+7,407
+24% +$472K 0.23% 114
2018
Q2
$1.94M Buy
30,581
+16
+0.1% +$903 0.15% 146
2018
Q1
$1.74M Sell
30,565
-12
-0% -$648 0.15% 142
2017
Q4
$1.63M Buy
30,577
+1,520
+5% +$84.3K 0.14% 166
2017
Q3
$1.76M Sell
29,057
-722
-2% -$43.8K 0.21% 125
2017
Q2
$1.8M Sell
29,779
-151
-0.5% -$9.19K 0.22% 124
2017
Q1
$1.83M Buy
29,930
+2,566
+9% +$156K 0.23% 121
2016
Q4
$1.57M Buy
27,364
+141
+0.5% +$8.25K 0.21% 124
2016
Q3
$1.6M Sell
27,223
-77
-0.3% -$4.5K 0.23% 119
2016
Q2
$1.53M Sell
27,300
-100
-0.4% -$5.32K 0.22% 122
2016
Q1
$1.38M Buy
27,400
+241
+0.9% +$11.8K 0.21% 121
2015
Q4
$1.31M Sell
27,159
-610
-2% -$30.8K 0.23% 115
2015
Q3
$1.42M Buy
27,769
+3,328
+14% +$177K 0.24% 100
2015
Q2
$1.33M Buy
24,441
+1,906
+8% +$107K 0.23% 105
2015
Q1
$1.24M Buy
22,535
+2,563
+13% +$145K 0.21% 111
2014
Q4
$1.2M Buy
19,972
+465
+2% +$25.9K 0.22% 110
2014
Q3
$1.1M Buy
19,507
+8,406
+76% +$472K 0.22% 121
2014
Q2
$613K Buy
11,101
+212
+2% +$11.6K 0.14% 137
2014
Q1
$590K Buy
10,889
+76
+0.7% +$3.94K 0.16% 129
2013
Q4
$516K Sell
10,813
-374
-3% -$17.1K 0.14% 144
2013
Q3
$508K Buy
11,187
+341
+3% +$15.6K 0.16% 137
2013
Q2
$481K Buy
+10,846
New +$484K 0.16% 136

Other funds holding MRK

Carnegie Investment Counsel's MRK Position: Q1 2026 in Review

Carnegie Investment Counsel reduced its Merck (MRK) stake by 1.4% in Q1 2026, selling an estimated $145K and leaving 85,461 shares worth $10.3M. The position accounts for 0.2% of the portfolio, ranked #130.

Carnegie Investment Counsel first reported a position in MRK in Q2 2013 and has held it in 52 quarters since. 3,779 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Carnegie Investment Counsel held 85,461 shares of Merck worth $10.3M as of Q1 2026.
  • Carnegie Investment Counsel sold 1,254 Merck shares in Q1 2026, an estimated $145K.
  • Merck made up 0.2% of Carnegie Investment Counsel's portfolio in Q1 2026, its #130 holding.
  • Carnegie Investment Counsel first reported a position in Merck in Q2 2013 and has held it in 52 quarters since.
  • 3,779 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Carnegie Investment Counsel's 13F filing for Q1 2026, filed 1 May 2026.